Maven Securities’s Aura Biosciences AURA Stock Holding History

Maven Securities’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$334K	–	331
2026 Q1	$334K	Buy	+50,000	New	+$287K	0.01%	372

Other funds holding AURA

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Maven Securities's AURA Position: Q2 2026 in Review

Maven Securities sold out of Aura Biosciences (AURA) in Q2 2026, closing a stake of 50,000 shares — an estimated $334K sold.

Maven Securities first reported a position in AURA in Q1 2026 and held it in 1 quarter. The position peaked at $334K in Q1 2026. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

Maven Securities reported no remaining Aura Biosciences position as of Q2 2026 after selling out during the quarter.
Maven Securities sold 50,000 Aura Biosciences shares in Q2 2026, an estimated $334K.
Maven Securities first reported a position in Aura Biosciences in Q1 2026 and held it in 1 quarter.
Maven Securities's Aura Biosciences position peaked at $334K in Q1 2026.
146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.